CytomX Therapeutics (CTMX) Lifted to Hold at BidaskClub

CytomX Therapeutics (NASDAQ:CTMX) was upgraded by BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday.

CTMX has been the subject of a number of other reports. Bank of America boosted their price objective on shares of CytomX Therapeutics from $34.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Zacks Investment Research lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, February 19th. ValuEngine upgraded shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, April 2nd. Jefferies Group boosted their price objective on shares of CytomX Therapeutics to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 8th. Finally, Cantor Fitzgerald set a $40.00 price objective on shares of CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, May 16th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. CytomX Therapeutics presently has a consensus rating of “Buy” and an average price target of $38.43.

Shares of CTMX opened at $25.29 on Wednesday. The company has a market capitalization of $966.92 million, a PE ratio of -21.80 and a beta of 0.95. CytomX Therapeutics has a fifty-two week low of $13.00 and a fifty-two week high of $35.00.

CytomX Therapeutics (NASDAQ:CTMX) last announced its quarterly earnings data on Wednesday, March 7th. The biotechnology company reported $0.02 earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.43) by $0.45. The firm had revenue of $27.07 million during the quarter, compared to analyst estimates of $10.70 million. CytomX Therapeutics had a negative net margin of 67.88% and a negative return on equity of 92.68%. research analysts predict that CytomX Therapeutics will post -1.47 earnings per share for the current year.

In related news, CFO Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $26.52, for a total value of $79,560.00. Following the transaction, the chief financial officer now directly owns 7,741 shares of the company’s stock, valued at $205,291.32. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Frederick W. Gluck sold 3,819 shares of CytomX Therapeutics stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $30.00, for a total transaction of $114,570.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 123,578 shares of company stock worth $3,633,036. 8.50% of the stock is owned by insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Swiss National Bank increased its stake in shares of CytomX Therapeutics by 6.6% in the first quarter. Swiss National Bank now owns 35,600 shares of the biotechnology company’s stock worth $1,013,000 after buying an additional 2,200 shares during the period. State Board of Administration of Florida Retirement System increased its stake in shares of CytomX Therapeutics by 28.8% in the first quarter. State Board of Administration of Florida Retirement System now owns 12,706 shares of the biotechnology company’s stock worth $361,000 after buying an additional 2,840 shares during the period. Allianz Asset Management GmbH increased its stake in shares of CytomX Therapeutics by 7.4% in the first quarter. Allianz Asset Management GmbH now owns 58,739 shares of the biotechnology company’s stock worth $1,671,000 after buying an additional 4,036 shares during the period. New York State Common Retirement Fund increased its stake in shares of CytomX Therapeutics by 10.4% in the first quarter. New York State Common Retirement Fund now owns 46,897 shares of the biotechnology company’s stock worth $1,334,000 after buying an additional 4,420 shares during the period. Finally, Iguana Healthcare Management LLC increased its stake in shares of CytomX Therapeutics by 7.1% in the fourth quarter. Iguana Healthcare Management LLC now owns 75,000 shares of the biotechnology company’s stock worth $1,583,000 after buying an additional 5,000 shares during the period. 75.97% of the stock is currently owned by institutional investors.

About CytomX Therapeutics

CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply